Please wait while the formulary information is being retrieved.
NEO-SYNALAR (NEOMYCIN SULFATE/FLUOCINOLONE ACETONIDE/EMOLLIENT COMB NO.65)
- Minor bacterial skin infections
- Skin inflammation
0.5 % (0.35 % base)-0.025 % topical cream
- Apply a thin layer to the affected area(s) by topical route 2-4 timesdaily
Kit 0.5 % (0.35 % base)-0.025 % topical cream
- Dosage information is not available
Minor bacterial skin infections
- Apply a thin layer to the affected area(s) by topical route 2 times per day
- Apply a thin layer to the affected area(s) by topical route 4 times per day
- Apply a thin layer to the affected area(s) by topical route 2-4 timesdaily
Skin inflammation
- Apply a thin layer to the affected area(s) by topical route 2 times per day
- Apply a thin layer to the affected area(s) by topical route 4 times per day
- Apply a thin layer to the affected area(s) by topical route 2-4 timesdaily
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Severe burns
Severe
Moderate
- Hypothalamic-pituitary insufficiency
- Large open wound
NEO-SYNALAR (NEOMYCIN SULFATE/FLUOCINOLONE ACETONIDE/EMOLLIENT COMB NO.65)
- Minor bacterial skin infections
- Skin inflammation
- Dermatitis due to topical drug
- Skin rash
- Erythema
- Stinging of skin
More Frequent
Severe
Less Severe
- Folliculitis
- Purpura
- Skin and skin structure infection
- Skin atrophy
- Headache disorder
- Paresthesia
- Pruritus of skin
- Skin rash
- Telangiectasia
- Treatment site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adrenal cortical insufficiency
- Bullous dermatitis
- Cataracts
- Central serous chorioretinopathy
- Glaucoma
- Hypothalamic-pituitary insufficiency
- Ocular hypertension
- Ototoxicity
- Skin hypopigmentation
- Skin striae
- Skin ulcer
- Urticaria
Less Severe
- Acneiform eruption
- Alopecia
- Blistering skin
- Contact dermatitis
- Dry skin
- Dyschromia
- Glycosuria
- Hirsutism
- Hypercortisolism
- Hyperesthesia
- Hyperglycemia
- Miliaria
- Perioral dermatitis
- Skin irritation
Contraindicated
None
Severe Precaution
Fluocinolone Acetonide
Risk of HPA-Axis suppression. Growth inhibition with chronic use.
- 1 Day – 18 Years
- Risk of HPA-Axis suppression. Growth inhibition with chronic use.
Management or Monitoring Precaution
None
Fluocinolone Acetonide
- Severity Level:
C
- Additional Notes: Systemic absorp unknown;poss risk of orofacial clefts w/systemic corticosteroids
Neomycin (topical)
- Severity Level:
2
- Additional Notes: Insufficient data available for topical product.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fluocinolone Acetonide
Amount of systemic absorption unknown, caution advised.
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Amount of systemic absorption unknown, caution advised. |
Neomycin (topical, Ophth)
Amount of systemic absorption unknown, caution advised.
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Fluocinolone Acetonide(topical)
Skin-Pre-existing skin atrophy increases risk of purpura and skin lacerations.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Minor bacterial skin infections | |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin inflammation | |
| L30.8 | Other specified dermatitis |
| L30.9 | Dermatitis, unspecified |
| 0-9 | A-Z |
|---|---|
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| L30.8 | Other specified dermatitis |
| L30.9 | Dermatitis, unspecified |
Formulary Reference Tool